arrow
S

Stephan Stilgenbauer

ulm university
H指数:126
被引数:7.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

In-frame variants in TP53 gene identified in adult leukemia samples are predominantly deleterious: a study of the TP53 Network of Education and Research Initiative on CLL

TP53基因中框变异在成人白血病样本中被鉴定为主要是致病的:TP53教育与研究中心 CLL研究倡议的一项研究

2026-09-260
OAAI
Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms

严重COVID-19中IL-1Ra和PGRN的自身抗体与炎症诱导的高磷酸化抗原异构体相关

2026-05-270
OAAI
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia

慢性淋巴细胞白血病患者免疫球蛋白重链增强子劫持的谱系

Leukemia
IF13.4
2026-04-230
OAAI
Overactivation of Cdc42 GTPase Impairs the Cytotoxic Function of NK Cells From Old Individuals Towards Senescent Fibroblasts

Cdc42 GTPase的过度活化损害了老年个体对衰老成纤维细胞的NK细胞的细胞毒性功能

2026-02-080
OAAI
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

德国和瑞士常规环境中,Brexucabtagene-autoleucel治疗复发/难治性套细胞淋巴瘤患者的疗效结果

2026-01-160
OAAI
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, O.; Stumpf, J.; Zhang, C.; Simon, F.; Bosch, F.; Feyzi, E.; Ghia, P.; Gregor, M.; Kater, A.P.; Lindström, V.; 等. 固定疗程与持续治疗在慢性淋巴细胞白血病中的应用比较. N. Engl. J. Med. 2025, 393, 24. [Google Scholar] [CrossRef]

2025-12-018
PRE
Overall survival outcomes with first-line continuous ibrutinib and fixed-duration ibrutinib-venetoclax treatments in patients with chronic lymphocytic leukemia: Comparison with an age-matched European population

慢性淋巴细胞白血病患者中,一线连续伊布替尼和固定周期伊布替尼-维奈克拉治疗的总生存结局:与年龄匹配的欧洲人群的比较

2025-10-280
OAAI
A non-coding mutation within the NOTCH1 gene initiates oncogenic NOTCH signaling via wild type NICD stabilization in CLL

NOTCH1基因内的非编码突变通过野生型NICD的稳定化在CLL中启动癌基因NOTCH信号通路

Blood
IF23.1
2025-07-120
OAAI
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice

慢性淋巴细胞白血病对靶向疗法的耐药性:临床和诊断实践中的现状与展望

Leukemia
IF13.4
2025-06-240
OAAI
GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migration

GPR15LG与CXCR4结合,并协同调节CXCL12诱导的细胞信号传导和迁移。

2025-05-200
OA
The significance of PAX5 in Merkel cell carcinoma

PAX5在 Merkel细胞癌中的意义

2025-03-040
OAAI
Future perspectives of fertility protection

生育保护的未来展望

2025-03-010
OAAI
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial

MRD指导下的zanubrutinib、venetoclax和obinutuzumab在复发性CLL中的应用:CLL2-BZAG试验的主要终点分析

BLOOD
IF23.1
2025-01-301
PRE
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report

利用Li-Fraumeni综合征患者体细胞癌基因驱动突变:铺就精准医学之路:一个病例报告

2025-01-160
OA